Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $3.98M fell 10.1% year over year, ahead of the -15.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -8.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.98M-0.2% QoQ
- Last fiscal yearDec 2025
- $16.98M-8.8% YoY
- LTMMar 2026
- $16.54M-15.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.1% | -100.0% | -89.9 pp |
| 1 year | -8.8% | -100.0% | -91.2 pp |
| 3-year CAGR | +10.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 16.98M USD
- Year-over-year change
- -8.8%
- 4-year CAGR
- +6.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.98M | -8.8% |
| FY2024 | 2024-12-31 | 18.61M | +46.7% |
| FY2023 | 2023-12-31 | 12.69M | -0.1% |
| FY2022 | 2022-12-31 | 12.7M | -3.3% |
| FY2021 | 2021-12-31 | 13.13M | — |
Selling, General & Admin vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 selling, general & admin of $16.54M is the lowest of the 11 companies compared; the peer median is $43.83M.
- Its year-over-year change of -15.6% is the 9th highest of 11, against a peer median of -3.7%.
- Over three fiscal years its annual growth of +10.2% compares with a peer median of +8.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $256.23M | +54.0% | +20.4% | 117.7% | |
| LTM Mar 2026 | $73.88M | +132.8% | +55.6% | 508.1% | |
| LTM Mar 2026 | $72.24M | -5.3% | -7.5% | 31.8% | |
| LTM Mar 2026 | $55.88M | -11.2% | -10.5% | — | |
| LTM Mar 2026 | $46.76M | -29.2% | -11.0% | 120.9% | |
| LTM Mar 2026 | $40.9M | +4.0% | +10.2% | 712.8% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
| LTM Mar 2026 | $33.2M | +76.0% | +43.8% | — | |
| LTM Mar 2026 | $30.28M | -34.0% | -12.3% | — | |
| LTM Mar 2026 | $27.31M | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $16.54M | -15.6% | +10.2% | — | |
| Peer median (excluding ELDN) | $43.83M | -3.7% | +8.4% | 120.9% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.74M | 27.08M | 30.31M | 51.96M | 66.27M |
| Selling, General & Admin | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M |
| Operating Expenses | 36.87M | 88.43M | 43M | 70.58M | 83.25M |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| EBITDA | (36.67M) | (39.41M) | (116.16M) | (35.39M) | (45.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.87M) | (88.43M) | (43M) | (70.58M) | (83.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7K | 462K | (73.54M) | 34.82M | 37.67M |
| Income Before Tax | (36.86M) | (87.97M) | (116.54M) | (35.75M) | (45.58M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.35M) | 0 | 0 | 431K | 35K |
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| EPS (Diluted) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| Weighted Avg Shares | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
| Weighted Avg Shares (Diluted) | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.